IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

CStone Pharmaceuticals / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/27882" target="_blank" data-smartkarma-citation="entities:27882:1">CStone Pharma (CSTONE HK)</a> is a biopharmaceutical company which is developing a pipeline of 14 drug candidates of which 9 are in clinical development. CStone has started pre-marketing for a Hong Kong IPO to raise around $400 million, according to press reports.<div class="content-highlight">CStone has four late-stage clinical drug candidates who are CS1001, invosidenib, avapritinib and CS3009. A key priority is to add on around 10 pivotal clinical trials for the late-stage drug candidates to advance them to commercialisation in China. Overall, we believe that the prospectus of the four late-stage clinical drug candidates is mixed.</div>

CStone Pharma (CSTONE HK) is a biopharmaceutical company which is developing a pipeline of 14 drug candidates of which 9 are in clinical development. CStone has started pre-marketing for a Hong Kong IPO to raise around $400 million, according to press reports.CStone has four late-stage clinical drug candidates who are CS1001, invosidenib, avapritinib and CS3009. A key priority is to add on around 10 pivotal clinical trials for the late-stage drug candidates to advance them to commercialisation in China. Overall, we believe that the prospectus of the four late-stage clinical drug candidates is mixed.

CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates

United States

Loxo Oncology Inc researches and develops cancer drugs. The company focuses on building small molecule cancer drugs for genetically defined patient subsets.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Loxo Oncology (LOXO US)

CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates

CStone Pharma (CSTONE HK) is a biopharmaceutical company which is developing a pipeline of 14 drug candidates of which 9 are in clinical...

Arun George

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)